Skip to main content
Premium Trial:

Request an Annual Quote

Driven by Clinical Business, Cepheid's Q3 Revenues Rise 24 Percent

NEW YORK (GenomeWeb News) – Cepheid’s third-quarter revenues grew 24 percent, and the firm posted a 36 percent rise in net loss in the three-month period ended Sept. 30.
The Sunnyvale, Calif.-based molecular diagnostics firm brought in revenues of $44.9 million for the quarter compared to $36.3 million in the comparable quarter of 2007.
System product sales decreased 12 percent to $14 million from $15.9 million, while reagent and disposables sales jumped by 57 percent to $28.4 million from $18.1 million.
Total clinical sales rose 43 percent to $29.6 million from $20.7 million, while industrial sales declined about 5 percent to $4.2 million from $4.4 million and biothreat sales dipped about 3 percent to $8.6 million from $8.9 million.
Cepheid CEO John Bishop said in a statement that the third-quarter revenue bump came from “very strong North American system placements” and increased sales of MRSA tests.
Cepheid’s net loss increased to $6.5 million, or $.11 per share, from $4.7 million, or $.09 per share, in the third quarter of 2007.
The company’s R&D spending increased 38 percent to $11.6 million from $8.4 million, while its SG&A costs grew 24 percent to $13.4 million from $10.8 million.
Cepheid finished the quarter with $24.4 million in cash and cash equivalents.
The company said it expects total revenue for 2008 to be in the range of $174 million to $176 million, and the company foresees a net loss for the year between $22.5 million and $23.5 million.
In early Wednesday trade on the Nasdaq, Cepheid’s shares were up nearly 13 percent at $10.43.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.